SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32nd International Symposium on ALS/MND taking place online from December 7 – December 10, 2021.
Oral Presentation
Session Title: Session 5: Autonomy and Decision Making
Presentation Title: IMPACT ALS Europe – a European Survey of People Living with ALS
Presenter: Mark Heverin, Research Manager, Academic Unit of Neurology, Trinity College Dublin
Presentation Number: C14
Date: December 8, 2021
Session Time: 4:50 – 6:00 PM GMT
Presentation Time: 5:30 – 5:45 PM GMT
Poster Presentations
Session Title: Live Poster Session A
Theme: 09 – Clinical Trials and Trial Design
Presentation Title: Relationship Between Quantitative Strength Changes and Functional Outcomes in the Phase 2 FORTITUDE-ALS Trial
Presenter: Bill Jacobsen, M.D., Neurologist, Gregory W. Fulton ALS and Neuromuscular Disease Center and Assistant Professor, Department of Neurology at the Barrow Neurological Institute
Poster Number: CLT-10
Date: December 7, 2021
Session Time: 4:50 – 6:20 PM GMT
Session Title: Live Poster Session A
Theme: 09 – Clinical Trials and Trial Design
Presentation Title: Update of COURAGE-ALS: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate Efficacy and Safety of Reldesemtiv in Patients with ALS
Presenter: Stacy Rudnicki, M.D., Vice President, Clinical Research, Cytokinetics
Poster Number: CLT-15
Date: December 7, 2021
Session Time: 4:50 – 6:20 PM GMT
Session Title: Live Poster Session C
Theme: 09 – Clinical Trials and Trial Design
Presentation Title: Grip Strength is More than a Number: The Relationship Between Grip Strength and Fine Motor and Arm Function in FORTITUDE-ALS
Presenter: Andrew Wolff, M.D., Senior Vice President, Senior Fellow, Clinical Research and Development, Cytokinetics
Poster Number: CLT-36
Date: December 9, 2021
Session Time: 4:50 – 6:20 PM GMT
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing a U.S. NDA submission of omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). The company has announced positive results from Cohorts 1 and 2 in REDWOOD-HCM, a Phase 2 clinical trial of aficamten in patients with obstructive HCM. Cytokinetics is conducting start-up activities for SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with ALS. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential benefits of reldesemtiv, including its ability to represent an additive and complementary approach to increase muscle function; Cytokinetics’ and its partners’ research and development activities; the timing of enrollment of patients in Cytokinetics’ and its partners’ clinical trials; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics’ drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials; and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for reldesemtiv; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
Contact:
Cytokinetics
Joanna Siegall
Senior Manager, Corporate Communications, Investor Relations
(425) 314-1721
